GSK boosts low-carbon inhaler development with PhIII trials, investment in French manufacturing facility
GSK is taking the next steps to develop a low-carbon alternative to its metered dose inhaler (MDI), Ventolin, through beginning Phase III clinical trials next …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.